ELTX
Elicio Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.55
−0.64%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.44
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.43
- EPS estimate
- -$0.54
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -4.9%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $16
- PT range
- $8.00 – $23
- Analysts
- 2
2 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.54 | -$0.43 | Beat 20.00% | — |
| May 11, 2026 | -$0.49 | -$0.65 | Miss -32.65% | — |
| Mar 12, 2026 | -$0.45 | -$0.49 | Miss -10.11% | — |
| Nov 13, 2025 | -$0.62 | -$0.60 | Beat 3.23% | — |
| Aug 7, 2025 | -$0.69 | -$0.66 | Beat 4.35% | — |
| Mar 31, 2025 | -$0.94 | -$1.02 | Miss -8.51% | $1.2M |
| May 15, 2024 | -$1.09 | -$1.15 | Miss -5.50% | — |
| Feb 13, 2024 | -$0.78 | -$1.75 | Miss -124.36% | — |
| Nov 9, 2023 | -$0.80 | -$1.27 | Miss -58.75% | — |
| Aug 11, 2023 | -$5.70 | -$2.61 | Beat 54.21% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026